- Home
- STI vs ATNM Comparison
STI vs ATNM Comparison
Compare STI & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STI
- ATNM
- Stock Information
- Founded
- STI 2014
- ATNM 2000
- Country
- STI United States
- ATNM United States
- Employees
- STI N/A
- ATNM N/A
- Industry
- STI
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- STI
- ATNM Health Care
- Exchange
- STI NYSE
- ATNM Nasdaq
- Market Cap
- STI 51.2M
- ATNM 56.5M
- IPO Year
- STI N/A
- ATNM N/A
- Fundamental
- Price
- STI $0.39
- ATNM $1.17
- Analyst Decision
- STI
- ATNM Strong Buy
- Analyst Count
- STI 0
- ATNM 4
- Target Price
- STI N/A
- ATNM $8.75
- AVG Volume (30 Days)
- STI 2.1M
- ATNM 166.1K
- Earning Date
- STI 03-04-2025
- ATNM 03-28-2025
- Dividend Yield
- STI N/A
- ATNM N/A
- EPS Growth
- STI N/A
- ATNM N/A
- EPS
- STI N/A
- ATNM N/A
- Revenue
- STI $5,329.00
- ATNM $81,000.00
- Revenue This Year
- STI N/A
- ATNM $138.42
- Revenue Next Year
- STI N/A
- ATNM $16,957.05
- P/E Ratio
- STI N/A
- ATNM N/A
- Revenue Growth
- STI 32.73
- ATNM N/A
- 52 Week Low
- STI $0.27
- ATNM $1.07
- 52 Week High
- STI $4.44
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- STI 42.70
- ATNM 46.97
- Support Level
- STI $0.39
- ATNM $1.15
- Resistance Level
- STI $0.43
- ATNM $1.29
- Average True Range (ATR)
- STI 0.03
- ATNM 0.07
- MACD
- STI 0.00
- ATNM 0.01
- Stochastic Oscillator
- STI 23.15
- ATNM 46.51
About STI SOLIDION TECHNOLOGY INC
Solidion Technology Inc is engaged in researching, developing and manufacturing battery materials and components, as well as the development and production of next-generation batteries for energy storage systems and electric vehicles for ground, air, and sea transportation. It is recognized as a global IP leader in both the high-capacity anode and the high-energy solid-state battery.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.